Abstract:As a promising radiotherapy technology, stereotactic body radiotherapy (SBRT) enables precise delivery of high-dose radiation in a short course. The characteristic of SBRT is that a high dose outside the target area decreases rapidly, which can ensure the therapeutic dose of the target area and can also minimize the exposure dose of the organ at risk around the target area when compared with regular radiotherapy. Currently, SBRT has become an effective treatment for early stage NSCLC especially for older patients when they are not suitable for operation. We have read with interest this article by Moreno et al.1Moreno A.C. Fellman B. Hobbs B.P. et al.Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage NSCLC.J Thorac Oncol. 2020; 15: 101-109Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar about the optimal dose for SBRT in patients with early NSCLC. Moreno et al.1Moreno A.C. Fellman B. Hobbs B.P. et al.Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage NSCLC.J Thorac Oncol. 2020; 15: 101-109Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar investigated a large cohort with over 20,500 patients. They found that 5-year overall survival (OS) rates were 26% for low biologically effective dose (BED) (BED10 < 130 Gy) and 34% for high BED (BED10 ≥ 130 Gy) groups (p = 0.039), suggesting that a BED10 of 130 Gy and above may confer an additional survival benefit. We would like to point out some concerns regarding this article. First, the authors should consider the competitive risk relationship between cancer-caused death and noncancer-caused death, which is highly related to age. In this article, 70% of patients are more than 70 years old. Thus, noncancer-caused death could be the primary reason for the death toll. Second, we wonder whether the age range was well-balanced between the low-BED and high-BED groups, because the authors only divided patients into two groups (age <70 y and age ≥70 y). We believe that the authors should perhaps need to divide the age into more stratifications (such as <70 y, 75–80 y, 80–85 y, >85 y) or consider the age as a continuous variable in propensity-score matching. Recent studies revealed that SBRT, combined with other treatments, was associated with improved survival. Grinnell et al.2Grinnell M. Appiah A.K. Baine M. et al.Adjuvant chemotherapy following SBRT for early stage non-small cell lung cancer (NSCLC) in older patients [e-pub ahead of print]. J Geriatr Oncol.https://doi.org/10.1016/j.jgo.2020.04.014Google Scholar found adjuvant chemotherapy after SBRT was associated with improved OS in patients more than 70 years old with tumors greater than or equal to 4 cm2. SBRT and immune checkpoint inhibition are rapidly growing and effective treatment modalities.3Käsmann L. Eze C. Manapov F. Stereotactic body radiation therapy (SBRT) combined with immune check-point inhibition (ICI) in advanced lung cancer: which metastatic site should be irradiated to induce immunogenic cell death?.Int J Radiation Oncol Biol Phys. 2020; 108: 225-226Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar In the randomized phase 2 study (PEMBRO-RT) trial, compared with pembrolizumab, SBRT followed by pembrolizumab revealed a doubling of the OS (15.9 mo versus 7.6 mo) and objective response rate (36% versus 18%) in advanced NSCLCs.4Theelen W.S.M.E. Peulen H.M.U. Lalezari F. et al.Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial.JAMA Oncol. 2019; 5: 1276-1282Crossref PubMed Scopus (243) Google Scholar These combinations greatly expand the application range of SBRT. As the population ages, there will be a higher proportion of patients who are suitable for SBRT. Therefore, SBRT is a promising method for future clinical applications.

The Critical Role of Stereotactic Body Radiation Therapy in Multimodal Treatment of Lung Metastasis from Bone and Soft Tissue Sarcomas

Stereotactic Body Radiation Therapy for Sarcoma Pulmonary Metastases

Stereotactic Body Radiotherapy for Metastatic and Recurrent Soft Tissue Sarcoma

Oligometastases Treated with Stereotactic Body Radiotherapy: Long-Term Follow-Up of Prospective Study

Stereotactic Ablative Brachytherapy with or Without Assistance of 3D-Printing Templates for Inoperable Locally Recurrent or Oligometastatic Soft-Tissue Sarcoma: a Multicenter Real-World Study.

Patient and Treatment Factors Associated with Improved Local Control and Survival in Oligometastatic Bone Disease: Results from a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy

Oligometastatic Breast Cancer Treated with Curative-Intent Stereotactic Body Radiation Therapy

Primary Stereotactic Body Radiotherapy for Spinal Bone Metastases from Lung Adenocarcinoma

Clinical Outcomes After Stereotactic Body Radiation Therapy for Nonspinal Bone Metastases: A Systematic Review and Meta-analysis

Stereotactic Body Radiation therapy for Liver Metastases: Systematic Review and Meta-Analysis With International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines

Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study

Stereotactic Body Radiation Therapy for Post-Pulmonary Lobectomy Isolated Lung Metastasis of Thoracic Tumor: Survival and Side Effects

Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control

Stereotactic body radiation therapy (SBRT) for the treatment of primary breast cancer in patients not undergoing surgery

Stereotactic Radiation Therapy (SRT) for Brain Metastases of Multiple Primary Tumors: A Single Institution Retrospective Analysis.

Promising Stereotactic Body Radiotherapy in NSCLC

Stereotactic body radiation therapy in non-liver colorectal metastases: a scoping review

Long-term disease outcome and volume-based decision strategy in a large cohort of multiple brain metastases treated with a mono-isocentric linac-based Stereotactic Radiosurgery technique

Early-Stage Non-Small Cell Lung Cancer Stereotactic Body Radiation Therapy Outcomes in a Single Institution

Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy

Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research